AnaptysBio Stock

AnaptysBio Dividend 2024

AnaptysBio Dividend

0 USD

AnaptysBio Dividend yield

Ticker

ANAB

ISIN

US0327241065

WKN

A2AJ8C

How much dividend does AnaptysBio 2024 pay?

According to the latest status from October 2024, AnaptysBio paid a total of 0 USD per share in dividends within the last 12 months. With the current AnaptysBio price of 35.03 USD, this corresponds to a dividend yield of 0 %. A dividend is paid times per year.

=

Historical AnaptysBio Dividends

A dividend is paid times per year. Last year, the payout months were and .

PaydateDividend

Is the AnaptysBio Dividend Safe?

AnaptysBio has been increasing the dividend for 0 years.

Over the past 10 years, AnaptysBio has increased it by an annual 0 %.

Over a five-year period, the distribution increased by 0%.

Analysts expect a Dividend Cut of -100% for the current fiscal year.

Dividend Details

Understanding AnaptysBio's Dividend Distributions

AnaptysBio’s dividends are a portion of the company’s profits distributed to shareholders. It is a critical indicator of the company’s financial health and attractiveness to investors. Dividends provide investors with a steady income stream, in addition to any profits that may come from selling the stock at a higher price than the purchase price.

Year-to-Year Comparison

Examining AnaptysBio's dividend distributions over the years can highlight the company’s profitability and stability. A consistent or increasing dividend payout can indicate a financially healthy company with predictable earnings, while fluctuations or reductions in dividends can suggest underlying financial or operational challenges.

Impact on Investments

AnaptysBio's dividend payments are an essential factor for income-focused investors. A robust dividend payout can enhance the stock’s appeal, offering regular income in addition to potential capital gains. It also can indicate the company's confidence in its future earnings, making it a significant consideration in investment decisions.

Interpreting Dividend Fluctuations

Changes in AnaptysBio’s dividends can result from shifts in the company’s earnings, financial policies, or reinvestment strategies. An increase in dividends often signals financial stability, while a decrease may indicate a need to conserve cash or reinvest profits to fuel growth, each scenario having different implications for investors.

AnaptysBio Aktienanalyse

What does AnaptysBio do?

AnaptysBio Inc is a biopharmaceutical company founded in 2005 and headquartered in San Diego, California. The company focuses on researching, developing, and marketing novel therapeutic antibodies for the treatment of autoimmune diseases, inflammation, and cancer. AnaptysBio has a unique business model that aims to make antibody development more efficient and cost-effective. Instead of relying on traditional methods like the hybridoma technique, the company uses its proprietary SHM-XEL technology to isolate and identify human antibodies directly from B cells. This approach allows AnaptysBio to quickly find, test, and optimize high-quality antibody candidates, resulting in significantly shorter development times and lower costs. The company has two main divisions. The first division focuses on the development of antibodies for the treatment of autoimmune diseases and inflammation. In this division, AnaptysBio has several promising antibody candidates in its pipeline, including ANB020, an antibody against the immune system protein IL-33, being developed for the treatment of asthma and other allergic diseases. ANB019, an antibody against the immune system protein IL-36R, being developed for the treatment of inflammatory skin conditions such as psoriasis and atopic dermatitis, is another promising candidate. The second division of AnaptysBio focuses on the development of antibodies for the treatment of cancer. Here, the company has formed a promising partnership with TESARO, a leading cancer therapy company. Together, they are developing an antibody called TSR-042 that targets the immune system protein PD-1 and is used for the treatment of various cancers such as lung cancer and bladder cancer. AnaptysBio also has several products on the market that are based on its proprietary SHM-XEL technology. These include Simponi (Golimumab), an antibody used for rheumatoid arthritis, Crohn's disease, and psoriasis, for which AnaptysBio developed the technology in partnership with Janssen Biotech. Over the years, AnaptysBio has received several significant awards and recognition for its innovative antibody development platforms and technologies. In 2017, the company was included in the Deloitte Technology Fast 500 list and received the Frost & Sullivan Technology Innovation Award for its SHM-XEL technology. Overall, AnaptysBio is an innovative biopharmaceutical company with a unique business model and a promising pipeline of antibody candidates for the treatment of autoimmune diseases, inflammation, and cancer. Through its proprietary technology and partnerships with other companies, AnaptysBio remains well-positioned to continue providing innovative therapeutic solutions for patients. AnaptysBio is one of the most popular companies on Eulerpool.com.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Frequently Asked Questions about AnaptysBio stock

How much dividend does AnaptysBio pay?

Over the past 12 months, AnaptysBio paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, AnaptysBio is expected to pay a dividend of 0 USD.

What is the dividend yield of AnaptysBio?

The current dividend yield of AnaptysBio is .

When does AnaptysBio pay dividends?

AnaptysBio pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of AnaptysBio?

AnaptysBio paid dividends every year for the past 0 years.

What is the dividend of AnaptysBio?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is AnaptysBio located?

AnaptysBio is assigned to the 'Health' sector.

Wann musste ich die Aktien von AnaptysBio kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of AnaptysBio from 10/4/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/4/2024.

When did AnaptysBio pay the last dividend?

The last dividend was paid out on 10/4/2024.

What was the dividend of AnaptysBio in the year 2023?

In the year 2023, AnaptysBio distributed 0 USD as dividends.

In which currency does AnaptysBio pay out the dividend?

The dividends of AnaptysBio are distributed in USD.

Andere Kennzahlen von AnaptysBio

Our stock analysis for AnaptysBio Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of AnaptysBio Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.